Navigation Links
Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference
Date:7/30/2009

NEW YORK, July 30 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company and a leading developer of oncology compounds directed to cancer stem cell targets, today announced that the Company's CEO, Ivan Bergstein M.D. has been invited to present at the New Frontiers in Cancer Drug Development conference which is part of IBC's Drug Discovery and Development Week in Boston, MA. Dr. Bergstein's presentation, entitled "Developing Drug Candidates Directed to Cancer Stem Cell Targets: Preclinical and Clinical Update" is scheduled for 9:50AM on Wednesday August 5(th) at the World Trade Center/Seaport Hotel in Boston. Dr. Bergstein has also been invited to participate in a panel discussion following the presentations.

Cancer stem cell targeted therapeutics have emerged as the next frontier in the fight against cancer. As such, this field is significantly influencing current decision making with respect to oncology drug development. With this in mind, Dr. Bergstein's presentation will cover novel pre-clinical and clinical development paradigms, including human trial design, of drug candidates that target cancer stem cells. The talk will also feature Stemline's latest clinical data, as well as results from its pre-clinical pipeline and drug discovery platforms.

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biotechnology company developing novel oncology compounds directed to cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human clinical trial. Stemline is also developing a portfolio of biological and small molecule compounds directed at multiple high value cancer stem cell targ
'/>"/>

SOURCE Stemline Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Stemline Therapeutics Raises $12.5 Million
2. Cornerstone Therapeutics Announces Closing of Chiesi Transaction
3. Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date
4. PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
5. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
6. United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
7. Cell Therapeutics, Inc. Announces Exercise of Overallotment
8. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
9. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
10. Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics
11. Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Missouri (PRWEB) December 23, 2014 GMO ... Swiss biotechnology company, Syngenta, are in the process of ... proceedings. The consolidated case is In Re: Syngenta AG ... U.S. District Court for the District of Kansas. , ... has been handed over to U.S. District Judge John ...
(Date:12/24/2014)... December 23, 2014 The ... such as its definition, classification, application and ... specification, manufacturing process, and product cost structure. ... applications. The analysis also covers upstream raw ... industry development trend and proposals. In the ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, ... focused on gynecologic disease, announced today that investors ... , Birchview Fund LLC and several Vermillion directors ... unregistered shares of Vermillion,s common stock and warrants ... in a private placement.  Under ...
(Date:12/22/2014)... The Center for Professional Innovation ... training across the life sciences industry, has partnered with ... to provide the organization's members with discounted classroom courses, ... the more than 350 sessions across 80 course titles. ... when registering for a public course at ...
Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... Md., Oct. 12 Sequella, Inc., a clinical-stage ... treat life-threatening infectious diseases, today announced that it ... (SBIR) grant from the National Institutes of Health ... (NIAID) for the development of SQ641, Sequella,s lead ...
... Calif., Oct. 12 Raptor Pharmaceutical Corp. ("Raptor" or ... from the completed treatment phase of its open-label Phase ... in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive ... 5% of the U.S. population. At the completion of ...
... , ... singer, Cynthia Basinet petitions the United Nations Sixty-fourth General Assembly Fourth Committee on behalf ... ... and singer, Cynthia Basinet petitions the United Nations Sixty-fourth General Assembly Fourth Committee on ...
Cached Biology Technology:Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline 2Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline 3Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 2Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 3Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 4Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 5Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) 6Actress and Singer, Cynthia Basinet Petitions United Nations 2
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... entertainer and security consultant, Apollo Robbins for ... smart wallet.  Apollo Robbins ... 7 th , 2015, demonstrating some of his famous ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics ... pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred ... has served as a meeting place for peoples from ... the ongoing mixing of peoples with African, European, and ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... Vertebral fractures are a common cause of ... powerful predictors of future spine and hip fractures. ... simply fail to recognize vertebral fractures in their ... intervention is often not initiated. The Vertebral ...
... CHICAGO, IL (May 8, 2011) Research being ... individuals for hepatitis C based on age instead of ... well as prevent liver disease. Additionally, the rate of ... disease and type 2 diabetes is relatively low, and ...
... the Faculty of Medicine & Dentistry at the University ... kill neurons. This finding is significant because a specific ... medical community as a potential treatment for MS and ... post-doctoral fellow, Yohannes Haile, both from the Division of ...
Cached Biology News:New IOF teaching tool helps health professionals identify vertebral fractures 2Strides in identifying and improving screening practices and treatment for liver diseases 2Discovery demonstrates potential MS therapy could kill brain cells 2
Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
... Apoptosis is an evolutionarily conserved form of ... process. The central component of this ... called caspases. These enzymes participate in ... in response to pro-apoptotic signals and result ...
... DNA Visualizer Extraction Kit is manufactured for ... DNA damage byexposure to UV light. The ... is often used for DNA-cloning work. The ... bromide and exposure of UV light damages ...
...
Biology Products: